Therapeutic insights into “awakening the sleeping angel” in mutant p53-expressing human tumors: MiR-103 increases the expression of tumor suppressor p53 homologue TAp73 and induces regression of p53-mutated human tumors via down regulation of its target gene, 28/November/2016, 6.24 am

Molecular therapy for Myocardial Infarction: Long ncRNA NEAT improves myocardial function after myocardial infarction via up-regulation of PNUTS, 27/November/2016, 10.14 pm
November 27, 2016
Molecular therapy for Myocardial Infarction: MiR-301 improves myocardial function after myocardial infarction via up-regulation of PNUTS, 28/November/2016, 12.22 pm
November 28, 2016
Show all

From Significance of the study to Public health relevance:

Given that: (1) Cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors.; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant p53-overexpressing tumors; (4) cancer causes the highest economic loss compared to all the known causes of death worldwide; and (5) cancer causes the considerable economic loss worldwide, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; (ii) a side-effect-free natural product-based drug; and (iii) a way to effectively treat and stall metastatic progression and relapse of mutant p53-overexpressing human cancers.


From therapeutic strategy to Research Findings:

This study suggests a therapeutic strategy for stalling the progression of p53-deficient/deleted or mutant-p53 expressing human metastatic cancers. By activating tumor suppressor p53’s unmutated or rarely mutated “homologous protein such as TAp73” in p53-deficient or mutant-p53 expressing human metastatic cancers, one can stall them.

MiRNA103, by decreasing the expression of its target genes, it may increase the expression of tumor suppressor TAp73 (figure 1). Thereby, it may inhibit the migration and invasion of metastatic cancer cells expressing mutant-p53.

mir-103-activates-p73

Figure 1. MiR-103 functions as an activator of  TAp73 expression in human metastatic mutant-p53 expressing tumors


Therapeutic opportunity:

Given the ability of MiR-103 to induce the expression of TAp73 in p53-mutated human tumors, pharmacological formulations encompassing “MiRNA-103 or its activators” may be used to inhibit the progression of p53-mutated invasive metastatic tumors.

price-100

Together, this study suggests an MiRNA-based therapy for p53-mutated metastatic human tumors.[easy_payment currency=”USD”]


Details of the research findings

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $100#

Undisclosed mechanistic information: How MiR-103 increases the expression of TAp73

For purchase and payment details, you may reach us at admin@genomediscovery.org

#Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Therapeutic insights into “awakening the sleeping angel” in mutant p53-expressing human tumors: MiR-103 increases the expression of tumor suppressor p53 homologue TAp73 and induces regression of p53-mutated human tumors via down regulation of its target gene, 28/November/2016, 6.24 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.